Bladder, kidney, and other urologic cancers:
Indications for: Cisplatin
Advanced bladder cancer.
Adult Dosage:
Administer pre- and post-treatment antiemetics as appropriate. Give by slow IV infusion. 50–70mg/m2 IV per cycle once every 3–4 weeks. Heavily pretreated patients: initially 50mg/m2 IV per cycle every 4 weeks. Subsequent cycles, other dosages, combination regimens, dose modifications: see full labeling.
Children Dosage:
Not recommended.
Boxed Warning:
Nephrotoxicity. Peripheral neuropathy. Nausea and vomiting. Myelosuppression.
Cisplatin Warnings/Precautions:
Risk of dose-related nephrotoxicity or peripheral neuropathy, serious nausea, vomiting and myelosuppression. Baseline renal impairment or significant reductions in CrCl during therapy; reduce dose or consider alternatives. Monitor serum creatinine, BUN, CrCl, and electrolytes prior to initiation and as clinically indicated. Maintain adequate hydration before, during, and for 24hrs after dose. Consider magnesium supplementation as needed. Do baseline and periodic neurologic exam; consider discontinuation if Grade 3–4 neuropathy develops. Monitor blood counts before initiation, before each subsequent courses, and as clinically indicated. Monitor for infection. Have supportive equipment and medications readily available. Monitor audiometric and vestibular function (esp. children). Avoid extravasation. Elderly. Embryo-fetal toxicity. Use effective contraception during and for 14 months (females) or 11 months (males w. female partners) after last dose. Pregnancy; exclude status before initiation. Nursing mothers: not recommended.
Cisplatin Classification:
Platinum coordination complex.
Cisplatin Interactions:
Potentiates nephrotoxicity with other nephrotoxic drugs. Increased ototoxicity with other ototoxic drugs. Avoid contact with aluminum (eg, needles, IV sets).
Adverse Reactions:
Nephrotoxicity, peripheral neuropathy, nausea, vomiting, myelosuppression, ototoxicity; hypersensitivity reactions (monitor), ocular toxicity, secondary malignancies, inj site reactions, impaired fertility.
Note:
Formerly known under the brand name Platinol.
How Supplied:
Contact supplier
Gynecologic Cancers:
Prostate and other male cancers:
Indications for: Cisplatin
Advanced testicular cancer.
Adult Dosage:
Administer pre- and post-treatment antiemetics as appropriate. Give by slow IV infusion. 20mg/m2 IV daily for 5 days per cycle. Subsequent cycles, other dosages, combination regimens, dose modifications: see full labeling.
Children Dosage:
Not recommended.
Boxed Warning:
Nephrotoxicity. Peripheral neuropathy. Nausea and vomiting. Myelosuppression.
Cisplatin Warnings/Precautions:
Risk of dose-related nephrotoxicity or peripheral neuropathy, serious nausea, vomiting and myelosuppression. Baseline renal impairment or significant reductions in CrCl during therapy; reduce dose or consider alternatives. Monitor serum creatinine, BUN, CrCl, and electrolytes prior to initiation and as clinically indicated. Maintain adequate hydration before, during, and for 24hrs after dose. Consider magnesium supplementation as needed. Do baseline and periodic neurologic exam; consider discontinuation if Grade 3–4 neuropathy develops. Monitor blood counts before initiation, before each subsequent courses, and as clinically indicated. Monitor for infection. Have supportive equipment and medications readily available. Monitor audiometric and vestibular function (esp. children). Avoid extravasation. Elderly. Embryo-fetal toxicity. Use effective contraception during and for 14 months (females) or 11 months (males w. female partners) after last dose. Pregnancy; exclude status before initiation. Nursing mothers: not recommended.
Cisplatin Classification:
Platinum coordination complex.
Cisplatin Interactions:
Potentiates nephrotoxicity with other nephrotoxic drugs. Increased ototoxicity with other ototoxic drugs. Avoid contact with aluminum (eg, needles, IV sets).
Adverse Reactions:
Nephrotoxicity, peripheral neuropathy, nausea, vomiting, myelosuppression, ototoxicity; hypersensitivity reactions (monitor), ocular toxicity, secondary malignancies, inj site reactions, impaired fertility.
Note:
Formerly known under the brand name Platinol.
How Supplied:
Contact supplier
